Idioma:

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

Perl, Alexander E ; Martinelli, Giovanni ; Cortes, Jorge E ; Neubauer, Andreas ; Berman, Ellin ; Paolini, Stefania ; Montesinos, Pau ; Baer, Maria R ; Larson, Richard A ; Ustun, Celalettin ; Fabbiano, Francesco ; Erba, Harry P ; Di Stasi, Antonio ; Stuart, Robert ; Olin, Rebecca ; Kasner, Margaret ; Ciceri, Fabio ; Chou, Wen-Chien ; Podoltsev, Nikolai ; Recher, Christian ; Yokoyama, Hisayuki ; Hosono, Naoko ; Yoon, Sung-Soo ; Lee, Je-Hwan ; Pardee, Timothy ; Fathi, Amir T ; Liu, Chaofeng ; Hasabou, Nahla ; Liu, Xuan ; Bahceci, Erkut ; Levis, Mark J

The New England journal of medicine, 2019-10, Vol.381 (18), p.1728-1740 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
Autor: Perl, Alexander E ; Martinelli, Giovanni ; Cortes, Jorge E ; Neubauer, Andreas ; Berman, Ellin ; Paolini, Stefania ; Montesinos, Pau ; Baer, Maria R ; Larson, Richard A ; Ustun, Celalettin ; Fabbiano, Francesco ; Erba, Harry P ; Di Stasi, Antonio ; Stuart, Robert ; Olin, Rebecca ; Kasner, Margaret ; Ciceri, Fabio ; Chou, Wen-Chien ; Podoltsev, Nikolai ; Recher, Christian ; Yokoyama, Hisayuki ; Hosono, Naoko ; Yoon, Sung-Soo ; Lee, Je-Hwan ; Pardee, Timothy ; Fathi, Amir T ; Liu, Chaofeng ; Hasabou, Nahla ; Liu, Xuan ; Bahceci, Erkut ; Levis, Mark J
Assuntos: Acute myeloid leukemia ; Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Aniline Compounds - adverse effects ; Aniline Compounds - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Chemotherapy ; Death ; Drug Resistance, Neoplasm ; Female ; Flt3 protein ; fms-Like Tyrosine Kinase 3 - genetics ; Follow-Up Studies ; Humans ; Laboratories ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - mortality ; Liver - drug effects ; Male ; Medical prognosis ; Middle Aged ; Mutation ; Myeloid leukemia ; Neutropenia ; Pharmaceuticals ; Protein-tyrosine kinase ; Pyrazines - adverse effects ; Pyrazines - therapeutic use ; Recurrence ; Remission ; Remission Induction ; Salvage Therapy ; Survival ; Survival Analysis ; Thrombocytopenia
É parte de: The New England journal of medicine, 2019-10, Vol.381 (18), p.1728-1740
Descrição: Oral use of the selective FLT3 kinase inhibitor gilteritinib in patients who had relapsed or refractory acute myeloid leukemia with FLT3 mutations led to a median overall survival of 9.3 months (vs. 5.6 months with standard chemotherapy) and complete remission with full or partial hematologic recovery in 34.0% of patients (vs. 15.3%).
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 3 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.